{"title": "EU lists rare nerve disorder as possible side-effect of AstraZeneca COVID-19 vaccine", "author": "Reuters", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-lists-rare-nerve-disorder-possible-side-effect-astrazeneca-covid-19-vaccine-2021-09-08/", "hostname": "reuters.com", "description": "Europe's medicines regulator has added an extremely rare nerve-damaging disorder, Guillain-Barr\u00e9 syndrome, as a possible side-effect of AstraZeneca's COVID-19 vaccine, regular safety updates from the watchdog showed on Wednesday.", "sitename": "Reuters", "date": "2021-09-08", "cleaned_text": "EU lists rare nerve disorder as possible side-effect of AstraZeneca COVID-19 vaccine Sept 8 (Reuters) - Europe's medicines regulator has added an extremely rare nerve-damaging disorder, Guillain-Barr\u00e9 syndrome, as a possible side-effect of AstraZeneca's [(AZN.L)](https://www.reuters.com/companies/AZN.L/) COVID-19 vaccine, regular safety updates from the watchdog showed on Wednesday. The European Medicines Agency said a causal relationship between GBS and the AstraZeneca shot, known as Vaxzevria, was a \"at least a reasonable possibility\" after 833 cases of GBS were reported out of 592 million doses of the vaccine given worldwide by July 31. The EMA categorised the side-effect as \"very rare\", the lowest frequency of side-effect category it has, and has emphasised that the benefits of the shot outweigh the risks. The U.S. Food and Drug Administration has added a warning over Guillain-Barr\u00e9 syndrome as a possible side-effect of Johnson & Johnson's [(JNJ.N)](https://www.reuters.com/companies/JNJ.N/) shot. Both vaccines use viral vector technology, and have also been associated with rare blood clots. [ read more ](/business/healthcare-pharmaceuticals/jj-vaccine-benefits-outweigh-its-risks-despite-reports-neurological-disorder-cdc-2021-07-22/) The EMA also tagged some other less severe side-effects to vaccines from Johnson & Johnson [(JNJ.N)](https://www.reuters.com/companies/JNJ.N/), Moderna as well as AstraZeneca's shot. Reporting by in Bengaluru; Ganguli "}